Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
6.82
+0.40 (6.23%)
Real-time:   12:59PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.50 - 6.91
52 week 3.10 - 7.45
Open 6.54
Vol / Avg. 622,684.00/1.02M
Mkt cap 462.83M
P/E 143.37
Div/yield     -
EPS 0.05
Shares 69.56M
Beta 1.44
Inst. own 81%
Nov 24, 2014
Progenics Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference Add to calendar
Nov 20, 2014
Progenics Pharmaceuticals Inc at Jefferies Global Heatlhcare Conference - London
Nov 18, 2014
Progenics Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 7, 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Release
Nov 7, 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 88.76% -541.49%
Operating margin 88.19% -546.68%
EBITD margin - -534.74%
Return on average assets 97.41% -44.61%
Return on average equity 126.74% -58.50%
Employees 69 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters